专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06835742B2 Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release 有权
标题翻译：氨氯地平和阿托伐他汀对胆固醇晶体形成抑制和主动脉内皮细胞一氧化氮释放的协同作用
公开(公告)号：US06835742B2
公开(公告)日：2004-12-28
申请号：US09921479
申请日：2001-08-03
申请人： R. Preston Mason
发明人： R. Preston Mason
IPC分类号： A61K3144
CPC分类号： A61K31/40 , A61K31/401 , A61K31/44 , A61K2300/00
摘要： The combination of the antihypertensive calcium channel blocker amlodipine and lipid-lowering agent atorvastatin inhibits free cholesterol crystallization in atherosclerotic-like membranes. In addition, treatment with a combination of amlodipine and atorvastatin results in a synergistic effect on the release of NO from rabbit aorta endothelial cells.
摘要翻译：抗高血压钙通道阻断剂氨氯地平和降脂药阿托伐他汀的组合抑制动脉粥样硬化样膜中的游离胆固醇结晶。此外，用氨氯地平和阿托伐他汀组合的治疗可以导致从兔主动脉内皮细胞释放NO的协同作用。

2. 发明授权

US07838552B2 Compositions comprising nebivolol 有权
公开(公告)号：US07838552B2
公开(公告)日：2010-11-23
申请号：US11273992
申请日：2005-11-15
申请人： Eric Davis , John P. O'Donnell , Peter Bruce Bottini , Andrew Shaw , R. Preston Mason
发明人： Eric Davis , John P. O'Donnell , Peter Bruce Bottini , Andrew Shaw , R. Preston Mason
IPC分类号： A61K31/352 , C07D311/04
CPC分类号： A61K31/40 , A61K31/54 , A61K45/06 , A61K2300/00
摘要： Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

3. 发明申请

US20090030071A1 Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol 审中-公开
标题翻译：使用奈比洛尔治疗墨西哥美国人心血管疾病
公开(公告)号：US20090030071A1
公开(公告)日：2009-01-29
申请号：US12173125
申请日：2008-07-15
申请人： Andrew A. Shaw , R. Preston Mason , Betty Riggs
发明人： Andrew A. Shaw , R. Preston Mason , Betty Riggs
IPC分类号： A61K31/352 , A61P9/00
CPC分类号： A61K31/352
摘要： Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such as, but not limited to, hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention relates to methods for treating and/or preventing cardiovascular disorders in persons of Hispanic descent, particularly Mexican Americans, using compositions comprising nebivolol.
摘要翻译：奈比洛尔已被证明对心血管疾病的治疗有益，例如但不限于高血压，充血性心力衰竭，动脉僵硬和内皮功能障碍。本发明涉及使用含有奈比洛尔的组合物治疗和/或预防西班牙裔血统特别是墨西哥裔美国人心血管疾病的方法。

4. 发明申请

US20080293679A1 Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors 审中-公开
标题翻译：使用类胡萝卜素和/或类胡萝卜素衍生物/类似物来减少/抑制COX抑制剂的某些负面影响
公开(公告)号：US20080293679A1
公开(公告)日：2008-11-27
申请号：US11417307
申请日：2006-05-02
申请人： Samuel F. Lockwood , R. Preston Mason
发明人： Samuel F. Lockwood , R. Preston Mason
IPC分类号： A61K31/6615 , A61K31/122 , A61K31/015 , A61K31/047 , A61K31/01
CPC分类号： A61K31/01 , A61K31/015 , A61K31/047 , A61K31/122 , A61K31/6615
摘要： Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.
摘要翻译：将类胡萝卜素，特别是叶黄素类胡萝卜素或虾青素，叶黄素，玉米黄质，lycoxanthin，番茄红素或番茄红素的类似物或衍生物施用于用COX-2抑制剂药物治疗的受试者可以减少至少一部分与给予COX-2选择性抑制药物。类胡萝卜素或其类似物或衍生物可以在COX-2选择性抑制剂药物治疗开始之前，同时或之后施用于受试者。类胡萝卜素或其类似物或衍生物可以与COX-2选择性抑制剂药物治疗同时给予受试者。类胡萝卜素或其类似物或衍生物可以与COX-2选择性抑制剂药物组合引入药物制剂中，或者可以分开施用。本文所述的类似物或衍生物的施用可以减少经历COX-2选择性抑制剂药物治疗的受试者的血清和浆细胞膜中LDL和其它脂质的过氧化。本文所述的类似物或衍生物的给药可以降低经历COX-2选择性抑制剂药物治疗的有害临床心血管事件的发生率。

5. 发明授权

US07129265B2 Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy 有权
公开(公告)号：US07129265B2
公开(公告)日：2006-10-31
申请号：US10033149
申请日：2001-10-19
申请人： R. Preston Mason
发明人： R. Preston Mason
IPC分类号： A61K31/40
CPC分类号： A61K31/44 , A61K31/401 , A61K31/4015 , A61K31/455 , A61K2300/00
摘要： The combination of amlodipine with atorvastatin metabolite shows a synergistic antioxidant effect on lipid peroxidation in human low-density lipoproteins and membrane vesicles enriched with polyunsaturated fatty acids. Inhibition of oxy-radical damage by this drug combination was observed at therapeutic levels in a manner that could not be reproduced by the combination of amlodipine with other statins or the natural antioxidant, vitamin E. The basis for this potent activity is attributed to the chemical structures of these compounds and their molecular interactions with phospholipid molecules, as determined by x-ray diffraction analyses. This combination therapy can be used to treat cardiovascular disorders, especially coronary artery disease, by increasing the resistance of low-density lipoproteins and vascular cell membranes against oxidative modification.

6. 发明申请

US20080161296A1 Compositions comprising nebivolol 有权
标题翻译：包含奈比洛尔的组合物
公开(公告)号：US20080161296A1
公开(公告)日：2008-07-03
申请号：US11273992
申请日：2005-11-15
申请人： Eric Davis , John P. O'Donnell , Peter Bruce Bottini , Andrew Shaw , R. Preston Mason
发明人： Eric Davis , John P. O'Donnell , Peter Bruce Bottini , Andrew Shaw , R. Preston Mason
IPC分类号： A61K31/54 , A61K31/40
CPC分类号： A61K31/40 , A61K31/54 , A61K45/06 , A61K2300/00
摘要： Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
摘要翻译：奈比洛尔已被证明对心血管疾病如高血压，充血性心力衰竭，动脉僵硬和内皮功能障碍的治疗有益。本发明的特征在于包含奈比洛尔和至少一种其它活性剂的药物组合物，其中所述至少一种其它活性剂是心血管药剂。

7. 发明授权

US08063101B2 Carotenoid analogs and derivatives for the prevention of platelet aggregation 有权
标题翻译：类胡萝卜素类似物和衍生物用于预防血小板聚集
公开(公告)号：US08063101B2
公开(公告)日：2011-11-22
申请号：US12079253
申请日：2008-03-24
申请人： Samuel F. Lockwood , R. Preston Mason
发明人： Samuel F. Lockwood , R. Preston Mason
IPC分类号： A61K31/335 , C07C403/24
CPC分类号： A61K31/01
摘要： The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation. Yet further embodiments provide for methods of treating a disorder associated with platelet aggregation that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting platelet aggregation in a subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional antiplatelet agents.
摘要翻译：目前描述的实施方案涉及包含用于治疗与血小板聚集相关的病症的一种或多种类胡萝卜素类似物或衍生物的组合物。某些实施方案提供了使用所述类胡萝卜素类似物或衍生物制备适用于这种治疗的组合物。另外的实施方案提供包含一种或多种类胡萝卜素类似物或衍生物与一种或多种适用于治疗与血小板聚集有关的病症的其它组合物或药物组合的药物组合物。另外的实施方案提供了治疗与血小板聚集相关的病症的方法，其包括向受试者受益，所述受试者适合于在经历所述治疗的受试者中抑制血小板聚集的药物组合物，并且包括类胡萝卜素类似物或衍生物，任选地与一种或多种另外的抗血小板药物组合。

8. 发明申请

US20090124574A1 Carotenoid analogs and derivatives for the prevention of platelet aggregation 有权
标题翻译：类胡萝卜素类似物和衍生物用于预防血小板聚集
公开(公告)号：US20090124574A1
公开(公告)日：2009-05-14
申请号：US12079253
申请日：2008-03-24
申请人： Samuel F. Lockwood , R. Preston Mason
发明人： Samuel F. Lockwood , R. Preston Mason
IPC分类号： A61K31/225 , A61P7/02 , A61K31/27 , A61K31/365 , A61K31/661 , A61K31/60 , A61K31/727 , A61K31/366 , A61K31/4365
CPC分类号： A61K31/01
摘要： The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation. Yet farther embodiments provide for methods of treating a disorder associated with platelet aggregation that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting platelet aggregation in a subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional antiplatelet agents.
摘要翻译：目前描述的实施方案涉及包含一种或多种类胡萝卜素类似物或衍生物用于治疗与血小板聚集相关的病症的组合物。某些实施方案提供了使用所述类胡萝卜素类似物或衍生物制备适用于这种治疗的组合物。另外的实施方案提供包含一种或多种类胡萝卜素类似物或衍生物与一种或多种适用于治疗与血小板聚集有关的病症的其它组合物或药物组合的药物组合物。更进一步的实施方案提供了治疗与血小板聚集相关的病症的方法，其包括向受治疗受试者施用适合于在经历所述治疗的受试者中抑制血小板聚集的药物组合物，并且包括类胡萝卜素类似物或衍生物，任选地与一种或多种另外的抗血小板药物组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式